Skip to content

13F-HR filed by Casdin Capital, LLC

Casdin Capital, LLC filed this 13F-HR for the quarter ended 2016-09-30, filed 2016-11-14, with 26 holding rows worth $123,498,000.

Accession
0001172661-16-004290
Filed
2016-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2016

A holdings report, 26 entries on the cover page, a total value of $123,498,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $123,498,000 with VALUE read as thousands by filing date, 13F file number 028-17113. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AGIOS PHARMACEUTICALS INC00847X104COM282,443$14,919,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM266,500$12,272,000thousands by filing date
Foundation Medicine Inc350465100COM415,000$9,690,000thousands by filing date
EVOLENT HEALTH INC CL A30050B101Stock385,000$9,479,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM287,000$8,524,000thousands by filing date
LOXO ONCOLOGY INC548862101COM291,000$7,618,000thousands by filing date
GENMARK DIAGNOSTICS INC372309104COM625,000$7,375,000thousands by filing date
SPARK THERAPEUTICS INC84652J103COM93,500$5,616,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM240,000$5,532,000thousands by filing date
KITE PHARMA INC49803L109COM90,000$5,027,000thousands by filing date
BLUEBIRD BIO INC09609G100COM60,000$4,067,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM110,000$3,966,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK276,500$3,321,000thousands by filing date
EPIZYME INC29428V104COM295,000$2,903,000thousands by filing date
EXACT SCIENCES CORP COM30063P105Stock155,000$2,878,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock39,000$2,643,000thousands by filing date
VERADIGM INC01988P108COMMON STOCK200,000$2,634,000thousands by filing date
MYOKARDIA INC62857M105COM160,000$2,614,000thousands by filing date
GENOMIC HEALTH, INC.37244C101COM90,000$2,603,000thousands by filing date
Medgenics Inc New58436Q203COM NEW375,000$2,089,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK127,500$1,999,000thousands by filing date
ISHARES TR464287556ISHARES BIOTECH5,000$1,447,000thousands by filing date
IGNYTA INC451731103COM195,000$1,227,000thousands by filing date
IONIS PHARMACEUTICALS INC COM462222100Stock33,000$1,209,000thousands by filing date
EDITAS MEDICINE INC28106W103COM85,470$1,152,000thousands by filing date
SYROS PHARMACEUTICALS INC87184Q107COM50,000$694,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-16-004290this filing2016-11-14acceptance time not in the bulk data set